Symptomatic COPD Patients Benefit from Triple Therapy

Among patients with moderate-to-severe chronic obstructive pulmonary disease, frequent exacerbations, or both, hospital admissions were lower with triple therapy.

“Triple therapy” for patients with chronic obstructive pulmonary disease (COPD) consists of a combination of a long-acting β-agonist (LABA), a long-acting muscarinic antagonist (LAMA), and an inhaled corticosteroid (ICS). The 2017 GOLD guidelines recommend step-up to triple therapy for patients with frequent exacerbations and moderate-to-severe symptoms, despite treatment with a LABA/LAMA combination.

In this industry-funded international study, 2691 patients with ≥1 COPD exacerbation in the past year were randomized to one of the following treatments for 1 year:

Fixed, single-inhaler triple therapy with the LAMA/LABA/ICS combination of glycopyrronium/formoterol/beclomethasone
Triple therapy administered via two inhalers (one containing formot…

Reviewing Author

David J. Amrol, MD

Disclosures

Speaker’s BureauAstraZeneca; Incyte

David J. Amrol, MD

Disclosures

Speaker’s BureauAstraZeneca; Incyte

Symptomatic COPD Patients Benefit from Triple Therapy

Topics

Reviewing Author